Risperidone 12.5mg, 25mg, 37.5mg, 50mg; per vial; pwd for long-acting IM inj after reconstitution. Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid ...

Johnson & Johnson (JNJ) has been one of the great health care and consumer products survivors of our lifetimes. Even the latest round of over-the-counter quality control flaws did not cripple the ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...

SAN FRANCISCO, May 19, 2009 – New data demonstrate that maintenance therapy with RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to ...

May 27, 2009 — The US Food and Drug Administration (FDA) has approved risperidone long-acting injection for use alone or with lithium or valproate in the treatment of bipolar I disorder; and ...

Prevention of relapse is a major goal of maintenance treatment in patients with psychotic disorders. We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an ...

Sept. 19, 2005 — The European Commission has approved exemestane tablets for the treatment of estrogen receptor–positive invasive early breast cancer after two to three years of initial adjuvant ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Weekly risperidone delivered via the Lynx platform ...

Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia. The literature ...

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.